Intralymphatic injections as a new administration route for allergen-specific immunotherapy

International Archives of Allergy and Immunology

Volumn 150, Issue 1, 2009, Pages 59-65

  Martínez Gómez, Julia M ^a   Johansen, Pål ^a   Erdmann, Iris ^a   Senti, Gabriela ^a   Crameri, Reto ^b   Kundig, Thomas M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

Allergen specific immunotherapy; Cat allergen; Th1 Th2 balance; Vaccination

Indexed keywords

ALLERGEN; ANTIGEN; BEE VENOM; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; PHOSPHOLIPASE A2; RECOMBINANT PROTEIN FEL D 1; UNCLASSIFIED DRUG;

ALLERGY; ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CAT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; INGUINAL LYMPH NODE; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RADIOACTIVITY; T LYMPHOCYTE; TH1 CELL;

ALLERGENS; ANIMALS; BEE VENOMS; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLYCOPROTEINS; HYPERSENSITIVITY; IMMUNOGLOBULIN G; INJECTIONS, INTRALYMPHATIC; MALE; MICE; PHOSPHOLIPASES A2; T-LYMPHOCYTES;

EID: 63349086255     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000210381     Document Type: Article

References (38)

1. Bousquet J, Lockey R, Malling HJ: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558-562. (Pubitemid 28487930)
2. Casale TB: Status of immunotherapy: current and future. J Allergy Clin Immunol 2004;113:1036-1039.
3. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O: Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608-613. (Pubitemid 41267135)
4. Larche M: Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 2007;119:906-909. (Pubitemid 46527841)
5. Riemer A, Scheiner O, Jensen-Jarolim E: Allergen mimotopes. Methods 2004;32:321-327.
6. Creticos PS, Chen YH, Schroeder JT: New approaches in immunotherapy: allergen vaccination with immunostimulatory DNA. Immunol Allergy Clin North Am 2004;24:569-581, v.
7. Johansen P, Senti G, Martinez Gomez JM, Storni T, von Beust BR, Wuthrich B, Bot A, Kundig TM: Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy 2005;35:1591-1598. (Pubitemid 43919793)
8. Santeliz JV, Nest GV, Traquina P, Larsen E, Wills-Karp M: Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002;109:455-462. (Pubitemid 34234196)
9. Jilek S, Walter E, Merkle HP, Corthesy B: Modulation of allergic responses in mice by using biodegradable poly(lactide-co-glycolide) microspheres. J Allergy Clin Immunol 2004;114:943-950. (Pubitemid 39330271)
10. Kundig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, Hennecke F, Sladko K, Jennings GT, Bachmann MF: Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006;117:1470-1476.
11. Martinez Gomez JM, Fischer S, Csaba N, Kundig TM, Merkle HP, Gander B, Johansen P: A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm Res 2007;24:1927-1935. (Pubitemid 47389249)
12. Barbey C, Donatelli-Dufour N, Batard P, Corradin G, Spertini F: Intranasal treatment with ovalbumin but not the major T cell epitope ovalbumin 323-339 generates interleukin-10 secreting T cells and results in the induction of allergen systemic tolerance. Clin Exp Allergy 2004;34:654-662. (Pubitemid 38534901)
13. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C: Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707-713. (Pubitemid 47320765)
14. Razafindratsita A, Saint-Lu N, Mascarell L, Berjont N, Bardon T, Betbeder D, Van Overtvelt L, Moingeon P: Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007;120:278-285. (Pubitemid 47411528)
15. Zinkernagel RM: Localization dose and time of antigens determine immune reactivity. Semin Immunol 2000;12:163-171; discussion 257-344.
16. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H: Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997;156:199-209. (Pubitemid 27197203)
17. Maloy KJ, Erdmann I, Basch V, Sierro S, Kramps TA, Zinkernagel RM, Oehen S, Kundig TM: Intralymphatic immunization enhances DNA vaccination. Proc Natl Acad Sci USA 2001;98:3299-3303. (Pubitemid 32220840)
18. Johansen P, Haffner AC, Koch F, Zepter K, Erdmann I, Maloy K, Simard JJ, Storni T, Senti G, Bot A, Wuthrich B, Kundig TM: Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 2005;35:568-574. (Pubitemid 40331333)
19. Kundig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, Lother H, Gessner A, Kuhlcke K, Ohashi PS, Hengartner H, et al: Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995;268:1343-1347.
20. Crameri R, Fluckiger S, Daigle I, Kundig T, Rhyner C: Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 2007;62:197-206. (Pubitemid 46090303)
21. Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC: Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005;116:377-383. (Pubitemid 41096546)
22. Beasley R: Worldwide variation in prevalence of sypmtoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998;351:1225-1232.
23. Wuthrich B, Schindler C, Medici TC, Zellweger JP, Leuenberger P: IgE levels, atopy markers and hay fever in relation to age, sex and smoking status in a normal adult Swiss population. SAPALDIA (Swiss Study on Air Pollution and Lung Diseases in Adults) Team. Int Arch Allergy Immunol 1996;111:396-402. (Pubitemid 26390342)
24. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-475. (Pubitemid 29372886)
25. Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, Pauli G, Caillaud D, Dubost R, Leynadier F, Vervloet D, Herman D, Galvain S, Andre C: Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999;54:249-260. (Pubitemid 29185286)
26. Nelson HS: Advances in upper airway diseases and allergen immunotherapy. J Allergy Clin Immunol 2005;115:676-684.
27. Passalacqua G, Guerra L, Pasquali M, Lombardi C, Canonica GW: Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 2004;93:3-12;quiz 12-13, 103.
28. Canonica GW, Passalacqua G: Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;111:437-448.
29. Bousquet J, Van Cauwenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147-S334.
30. Koopman G, Bogers WM, van Gils M, Koornstra W, Barnett S, Morein B, Lehner T, Heeney JL: Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques. J Med Virol 2007;79:474-482. (Pubitemid 46564344)
31. Trepel M, Arap W, Pasqualini R: Modulation of the immune response by systemic targeting of antigens to lymph nodes. Cancer Res 2001;61:8110-8112. (Pubitemid 33091599)
32. Lehner T, Wang Y, Ping L, Bergmeier L, Mitchell E, Cranage M, Hall G, Dennis M, Cook N, Doyle C, Jones I: The effect of route of immunization on mucosal immunity and protection. J Infect Dis 1999;179(suppl 3):S489-S492. (Pubitemid 29198405)
33. Spaner DE, Astsaturov I, Vogel T, Petrella T, Elias I, Burdett-Radoux S, Verma S, Iscoe N, Hamilton P, Berinstein NL: Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer 2006;106:890-899. (Pubitemid 43238457)
34. von Beust BR, Johansen P, Smith KA, Bot A, Storni T, Kundig TM: Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur J Immunol 2005;35:1869-1876. (Pubitemid 40862335)
35. Powell RJ, Frew AJ, Corrigan CJ, Durham SR: Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Allergy 2007;62:1335-1338.
36. Ruedl C, Bachmann MF, Kopf M: The antigen dose determines T helper subset development by regulation of CD40 ligand. Eur J Immunol 2000;30:2056-2064. (Pubitemid 30456202)
37. Min B, Paul WE: Basophils: in the spotlight at last. Nat Immunol 2008;9:223-225.
38. Senti G, Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, Simard JJ, Wüthrich B, Crameri R, Graf N, Johansen P, Kündig TM: Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008;105:17908-17912.